SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to significant community anticipation surrounding its pivotal role in next-generation AI data centers, particularly with its advanced power solutions crucial for high-density computing infrastructure. The company's upcoming participation in a key industry conference is fueling discussions, as many investors speculate on potential news catalysts and the high short interest driving a prospective squeeze.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu Crypto is trending due to its exceptionally active and fiercely loyal community, which is relentlessly building a permissionless brand with numerous real-world products and initiatives. The conversation centers on its evolution from a meme to a robust brand, showcasing significant IRL efforts and a strong conviction for long-term growth across multiple blockchains. Enthusiasts are actively encouraging early participation, emphasizing dedication to building and a unique value proposition in the crypto space.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a high-profile meeting between its CEO and President Trump, where Trump publicly praised the company's US-based chip manufacturing and the profitable government investment. This has sparked intense community discussion, with many anticipating significant partnerships and a successful foundry turnaround driven by new technologies, while others remain cautious, attributing the stock's momentum primarily to political influence rather than fundamental shifts.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is experiencing significant volatility and a pre-decision sell-off as the market reacts to the FDA's recent request for additional clarification on the clinical benefit of FILSPARI for the FSGS indication. While some investors view this information request as a strong signal for a potential Complete Response Letter or delay, leading to sharp declines, others are actively buying the dip, viewing the steep decline as an overreaction given the drug's strong efficacy and high unmet need. The community is actively debating whether this is a common regulatory step or a fundamental setback for a therapy poised to become the first approved treatment for FSGS, a rare kidney disorder.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is generating significant conversation driven by intense speculation around a potential acquisition, especially as the J.P. Morgan conference fuels rumors of a strategic buyer like Novartis eyeing its cardiovascular assets. The community is also closely monitoring ongoing legal proceedings concerning patent validity, with recent delays sparking varied interpretations, while strong preliminary financial results showing positive cash flow are contributing to a cautious optimism about the company's future value.

Ribbon Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 17, 2024 and is headquartered in Tokyo, Japan.

Ribbon Acquisition Corp. - Ordinary Shares - Class A

Ribbon Acquisition Corp. is attracting significant attention as a 'fresh SPAC,' with community discussions highlighting a recent vote and anticipation of a catalyst. Many are observing its small float and perceived low risk near its NAV, drawing comparisons to other SPACs that have seen rapid movements.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is generating significant buzz following promising Phase 1 clinical data for CTX310, demonstrating deep and durable lipid reductions without serious adverse events. This breakthrough, published in The New England Journal of Medicine, validates the company's in vivo gene-editing platform and excites the community about its potential as a "one-and-done" treatment for severe lipid disorders. Investors anticipate substantial market recognition for this development, alongside ongoing pipeline progress in a field gaining new regulatory support.

Monero

Monero (XMR) is trending strongly as its community champions it as the 'king of privacy' and the 'real Bitcoin' amid growing global discourse on digital anonymity. Despite discussions around regulatory scrutiny of privacy tokens, XMR demonstrates significant momentum, with users emphasizing its superior decentralization and robust technology over alternatives.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending amid intense debate, as investors grapple with its persistent stock decline despite new strategic AI partnerships and potential tailwinds from discussions around credit card interest rate caps. While many criticize management and predict further drops given recent analyst downgrades, a significant portion of the community views PYPL as profoundly undervalued, actively accumulating shares and anticipating a strong rebound.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is actively discussed following its acquisition of a mobile analysis facility that will dramatically expedite rare-earth assay results from its key Greenland project. This development aligns with intense geopolitical focus on Greenland's critical mineral potential, as the community eagerly anticipates outcomes from high-level U.S.-Danish-Greenlandic meetings and speculates on CRML's strategic importance in securing Western rare-earth supply chains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference

Arcturus Therapeutics (NASDAQ:ARCT) CEO and President Joe Payne outlined the company's current focus on messenger RNA (mRNA) therapeutics, emphasizing a leaner operating profile and a near-term set...

Arcturus Therapeutics (NASDAQ:ARCT) Price Target Cut to $7.00 by Analysts at Citigroup

Citigroup cut their price objective on Arcturus Therapeutics from $9.00 to $7.00 and set a "neutral" rating for the company in a research report on Tuesday...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve brokerages that are currently covering the firm...

Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving Average - Time to Sell?

Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell...

Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve ratings firms that are currently covering the...

ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know

Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.

Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200 Day Moving Average - Should You Sell?

Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200-Day Moving Average - Here's Why...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve research firms that are currently covering the stock, MarketBeat...

Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to "Hold"

Wall Street Zen upgraded shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$7.77
Prev Close	$6.78
Open	$7.08
Dividend Yield	0.00%
50-Day Moving Average	$7.16
Beta	1.77
Avg. Volume	708,007.23
PE Ratio	-3.06

52-Week High	$24.17
52-Week Low	$5.85
Market Capitalization	$192.65M
EPS (Annual)	-$3.00
Price to Book	0.91
Revenue Per Employee	$786,301.14
Enterprise Value/EBITDA	N/A

ARCT
Arcturus Therapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARCT News

ARCTArcturus Therapeutics Holdings Inc